The cost of healthcare in the U.S. remains outrageously high, despite massive government subsidies. The system is designed to ...

The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...

The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...

Recent health developments include HIV infections from organ transplants in Brazil, Sanofi's potential sale of a stake in its ...

The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

Here are some of the major companies whose stocks moved on the week’s news.

Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...

The FDA has approved Pfizer’s marstacimab under the brand name Hympavzi for adults and children with hemophilia A or B, ...

Activist investor Starboard Value accused Pfizer of pressuring its former CEO Ian Read and ex-CFO Frank D’Amelio to halt ...

Itovebi is approved to treat patients with PIK3CA-mutated HR-positive, HER2 negative metastatic breast cancer in combination ...